Glaukos Co. (NYSE:GKOS) Stock Position Raised by State Street Corp

State Street Corp grew its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 5.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 1,954,449 shares of the medical instruments supplier's stock after acquiring an additional 98,109 shares during the quarter. State Street Corp owned about 3.54% of Glaukos worth $254,626,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of GKOS. Stifel Financial Corp boosted its holdings in shares of Glaukos by 37.7% in the third quarter. Stifel Financial Corp now owns 4,230 shares of the medical instruments supplier's stock valued at $551,000 after acquiring an additional 1,157 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in Glaukos in the third quarter worth approximately $6,932,000. Polar Asset Management Partners Inc. lifted its position in Glaukos by 24.2% in the third quarter. Polar Asset Management Partners Inc. now owns 217,900 shares of the medical instruments supplier's stock worth $28,388,000 after purchasing an additional 42,500 shares during the period. HighTower Advisors LLC boosted its stake in Glaukos by 3.3% during the 3rd quarter. HighTower Advisors LLC now owns 3,207 shares of the medical instruments supplier's stock valued at $416,000 after purchasing an additional 103 shares in the last quarter. Finally, Cinctive Capital Management LP increased its position in shares of Glaukos by 18.5% during the 3rd quarter. Cinctive Capital Management LP now owns 61,983 shares of the medical instruments supplier's stock valued at $8,075,000 after purchasing an additional 9,683 shares during the period. Institutional investors own 99.04% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on GKOS. BTIG Research upped their price objective on Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Stephens raised shares of Glaukos to a "strong-buy" rating in a report on Monday, December 2nd. Piper Sandler set a $140.00 price objective on shares of Glaukos in a research note on Thursday, October 17th. Morgan Stanley downgraded shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 target price on the stock. in a report on Monday, December 2nd. Finally, StockNews.com upgraded shares of Glaukos from a "sell" rating to a "hold" rating in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $143.17.

Insider Buying and Selling

In related news, COO Joseph E. Gilliam sold 2,275 shares of the business's stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at approximately $14,198,425.93. The trade was a 2.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 6.40% of the company's stock.

Glaukos Trading Down 1.7 %

Glaukos stock traded down $2.43 during midday trading on Thursday, reaching $140.46. The stock had a trading volume of 360,124 shares, compared to its average volume of 569,308. Glaukos Co. has a twelve month low of $59.58 and a twelve month high of $147.65. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The firm has a market cap of $7.74 billion, a price-to-earnings ratio of -46.51 and a beta of 1.03. The firm's fifty day simple moving average is $136.10 and its two-hundred day simple moving average is $126.60.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The company had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. During the same quarter in the prior year, the company earned ($0.50) earnings per share. The company's revenue for the quarter was up 23.9% on a year-over-year basis. Equities analysts anticipate that Glaukos Co. will post -1.89 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.